Prof. Dr. med. Felix Mottaghy

nuclear medicine

User Score	Experience	Rating	Price Range	Publications	Online Consultations
95%	28 years	9.8/10	$$$$	665	No

Overview

Country, City

Germany, Aachen

Health facility

University Hospital Aachen

Medical unit

Department of nuclear medicine

About the doctor

Prof. Dr. med. Felix Mottaghy is an esteemed nuclear medicine specialist with 27 years of experience. He has demonstrated his expertise and dedication to the field throughout his career through various roles and accomplishments. Dr. Mottaghy obtained his medical degree from the Rhine-Westphalia University of Technology Aachen and completed his practical year in prestigious institutions such as the University of Utah and the University Hospital Aachen. He has worked as an intern, assistant physician, consultant, and associate professor in esteemed hospitals and universities, including the University Hospital Ulm, University Hospitals Leuven, and the Maastricht University. He is the head of the Department of Nuclear Medicine at the University Hospital Aachen. Dr. Mottaghy's specialization in nuclear medicine allows him to provide advanced diagnostic and treatment options for various conditions. In addition to his clinical work, Dr. Mottaghy is an accomplished researcher and has published many scientific articles totaling 661 publications. His research interests include prostate cancer treatment, brain tumor imaging, and developing innovative radiotracers for breast cancer. Dr. Mottaghy's extensive experience, dedication to his field, and significant research contributions make him an exceptional doctor. His expertise in nuclear medicine and commitment to improving patient care and advancing medical knowledge distinguish him as a top professional.

Skills & Expertise

Resume

CV (Curriculum Vitae)

Education

1990-1996 Studied human medicine at the Rhine-Westphalia University of Technology Aachen
1995-1996 Practical year at the Luisenhospital Aachen (surgery), at the University of Utah (internal medicine), and the University Hospital Aachen (neurology)
1997 1st and 2nd stage of the United States Medical Licensing Examination
1998 Degree of Doctor of Medical Sciences at the Rhine-Westphalia University of Technology Aachen
1998 Obtaining a license for medical practice
2000-2001 Scholarship of the German Research Foundation, Department of Neurology, Harvard University in Boston
2003 Obtaining specialization in nuclear medicine
2004 Habilitation

Experience

1997-1998 Intern, Department of nuclear medicine at the University Hospital Duesseldorf
1998 Intern, Department of neurology at the University Hospital Aachen
1998-2000 Assistant Physician, Department of nuclear medicine, medical facilities of the Heinrich Heine University at the Juelich Research Center
2000-2001 Research Fellow at Harvard Medical School in Boston
2001-2002 Assistant Physician, Department of nuclear medicine, medical facilities of the Heinrich Heine University at the Juelich Research Center
2002-2003 Acting Head of the Department of nuclear medicine, medical facilities of the Heinrich Heine University at the Juelich Research Center
2003-2006 Consultant and Associate Professor at the University Hospital Ulm
2003-2007 Deputy Head of Department at the University Hospitals Leuven
2009 Full Professor of nuclear medicine at the Rhine-Westphalia University of Technology Aachen
2009 Head, Department of nuclear medicine at the University Hospital Aachen
2010-2016 Head, Department of Nuclear Medicine at the Maastricht University
2016-2019 Deputy Head, Department of radiology and nuclear medicine at the Maastricht UMC+

Awards & Memberships

2007-2012 Advisor, Member of Task groups at the European Organisation for Research and Treatment of Cancer
Taught graduate students in various countries and was the principal investigator and scientific partner of various clinical and preclinical research programs
Project Leader 11 - Hybrid 18F sodium fluoride (NaF) positron emission tomography (PET)/magnetic resonance imaging (MRI) for the non-invasive identification of microcalcifications as a marker of arterial plaque vulnerability in human carotid and coronary arteries